Patent · US Active

Polypeptide

US11155596B2 · kind B2 · utility

0Cited by

1References

34Claims

0Family size

Assignee

AFFIBODY AB · SE

Inventors

Elisabet Wahlberg · Sigtuna, SE
Elin Gunneriusson · Hallsberg, SE

Key dates

Filing date	Oct 28, 2016
Grant date	Oct 26, 2021
Priority date	—
Expiry date	Dec 24, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.